Premium
Human papillomavirus genotyping as a predictor of high‐grade cervical dysplasia in women with mildly cytologic abnormalities: A two‐year follow‐up report
Author(s) -
Huang LeeWen,
Lin YuHung,
Pan HunShan,
Seow KokMin,
Lin ChingYu
Publication year - 2012
Publication title -
diagnostic cytopathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.417
H-Index - 65
eISSN - 1097-0339
pISSN - 8755-1039
DOI - 10.1002/dc.21591
Subject(s) - medicine , genotyping , dysplasia , cytology , human papillomavirus , gynecology , incidence (geometry) , cervical cancer , dna testing , genotype , pathology , cancer , biology , gene , biochemistry , physics , genetics , optics
High‐risk human papillomavirus (HR‐HPV) DNA testing has emerged as another testing modality for women with mildly cytologic abnormalities. We conducted a two‐year follow‐up study of 108 women with mildly abnormal cervical cytology for detection of CIN 2/3. A cervical swab sample was obtained for HPV genotyping by a HPV blot and histologic follow‐up results were correlated with HR‐HPV types. Of the 108 cases, 93 (86.1%) were positive for HR‐HPV DNA. HPV‐16 was detected in 45.1% of patients. CIN grade 2 or 3 was confirmed in 25 (23.1%) of the 108 women during the two‐year follow‐up period. The two‐year cumulative incidence rates of CIN 2/3 were 38.6% (17/44) among HPV‐16‐ positive women, but only 5.6% among HR‐HPV‐positive women without HPV‐16 or HPV‐18. The sensitivity of a positive HPV‐16 test for CIN 2/3 was 68.0%, the specificity was 67.5%. Our results demonstrated that the type‐specific HPV‐16 test increased sensitivity of detecting high‐grade cervical dysplasia for women who have mildly cytologic abnormalities. The implication of the present findings is that HPV genotyping may identify women with the greatest risk of high‐grade CIN. Diagn. Cytopathol. 2012. © 2010 Wiley Periodicals, Inc.